A major concern for cancer vaccines targeting self-tumor antigens is the risk of autoimmune sequelae. Although antitumor immunity correlates with autoimmune disease in some preclinical models, the mechanism(s) linking antitumor immunity and subsequent autoimmune pathology remain(s) to be determined. In the current study, we demonstrated that intradermal (i. 
INTRODUCTION
Identification of tumor-associated antigens from various human cancers and animal tumor models has promoted an increasing interest in the development of antigen-specific cancer vaccines. The major challenge faced by cancer vaccines is that many potential tumor antigens also are found on normal cells; therefore, immunization against cancer must overcome self-tolerance (1, 2) . The melanomaassociated antigens are prototypic self-tumor antigens. Melanocytes and melanoma cells express many of these antigens, such as gp100, tyrosinase-related protein 1 (Trp-1), Trp-2, and MART-1/Melan-A (2, 3) . Studies in a murine melanoma model have demonstrated that immune tolerance to mouse melanoma antigens can be overcome by genetic immunization using viral or nonviral vectors encoding antigen genes (4 -7). Furthermore, because human melanoma-associated antigens are highly homologous with murine counterparts, genetic immunization in mice can be enhanced further by incorporating human antigens, a strategy known as xenoimmunization (3, 8 -11) . Although the mechanisms underlying enhanced antimelanoma responses by genetic vaccination-expressing xenoantigens remain elusive, results from these studies have demonstrated that multiple components of the immune system are capable of recognizing these autoantigens, including CD8 ϩ T cells, CD4 ϩ T cells, and antibodies, which can lead to tumor eradication.
A major concern for cancer vaccines is that an efficient immune response against self-tumor antigens may increase the risk of autoimmune sequelae (12) . The induction of an effective immune response against Trp-1 or Trp-2 is associated with the damage of normal melanocytes manifested as vitiligo (depigmentation of patches of skin) in some animal studies of cancer vaccination (7, (13) (14) (15) . Concomitant occurrence of antitumor immunity and autoimmunity also has been observed in other nonmelanoma models (16 -18) . These results suggest that autoimmune destruction is an unavoidable consequence of effective antitumor immunity (7, 19, 20) . However, we and others have documented that tumor protection can be achieved in the absence of autoimmune disease (11, 21, 22) . The question remains whether the uncoupling of antitumor response and autoimmune pathology is caused by the differential regulation of these two events or whether it is a reflection of a mild immune response that can clean up a small number of tumor cells without causing apparent normal tissue destruction. To address this issue in the current study, we describe a vaccination model in which robust antitumor immunity can be dissociated from autoimmune vitiligo. Using recombinant adenoviruses (Ads) expressing murine Trp-2 (AdmTrp-2) or human Trp-2 (AdhTrp-2) as melanoma vaccines, we can measure quantitatively the magnitude of Trp-2-specific immune responses and readily correlate antitumor immunity with the development of autoimmune vitiligo. Results from these studies demonstrated that vitiligo does not occur unless autoreactive T cells are recruited into the skin by inflammatory stimuli, suggesting that autoimmunity is not an unavoidable consequence of antitumor vaccines.
ture Collection). Hybridoma ascites fluid (100 l) for each monoclonal antibody was diluted in PBS (total volume, 500 l) and injected i.p. Monoclonal antibodies were injected 2 days before tumor challenge and then injected once a week until all of the control animals grew tumors. Intracellular Cytokine Staining. Splenocytes were harvested from mice 14 days after immunization and stained for intracellular IFN-␥ following 6 h stimulation with 1 g/ml indicated peptides in the presence of 0.5 mg/ml of Brefeldin A (Sigma Chemical Co., St. Louis, MO) as described previously (23) .
In Vivo CTL Assay. Splenocytes from naive C57BL/6 mice were divided into two groups. One was pulsed with 1 g/ml Trp-2 peptide for 1 h at 37°C and then labeled with 5 M 5,6-carboxylfluorescein succinimidyl ester (CFSE). The other was incubated for 1 h at 37°C with 1 g/ml OVA peptide and labeled with 0.5 M CFSE. Five million cells from each group were mixed and injected into Trp-2-vaccinated mice. Six h after target cell transfer, splenocytes were harvested for analysis of cytolytic activity by fluorescenceactivated cell sorter. Percent-specific lysis was determined by comparison of fluorescent intensities between Trp-2-and OVA-pulsed populations using the formula described by Coles et al. (24) .
Western Blot Assay. Protein extracts were prepared by solubilizing 293 cells infected with AdhTrp-2 or AdLacZ and electrophoresed on 10% SDS-PAGE. Following electrophoretic transfer, nitrocellulose membranes were blotted with sera obtained by cardiac puncture 28 days postimmunization. A rabbit antiserum specific for hTrp-2 (␣PEP8 h; provided by Vincent Hearing, National Cancer Institute, Bethesda, MD) was used to verify the size of the hTrp-2 protein.
RESULTS
Development of Autoimmune Vitiligo Is Associated with Enhanced Vaccination Using hTrp-2 as a Xenoantigen. We and others have reported that the first generation of recombinant Ad can be used as an effective vector for gene-based cancer vaccination (25) (26) (27) (28) . To evaluate such a vaccination strategy in a murine melanoma model, we constructed Ad vectors expressing the mouse Trp-2 (AdmTrp-2) or human Trp-2 (AdhTrp-2) protein. Intradermal immunization of C57BL/6 mice with either AdmTrp-2 or AdhTrp-2 elicited protective immunity against challenge with B16F10 cells that express endogenous Trp-2 antigen (Fig. 1A) , confirming that Ad is a potent vaccination platform. Mice immunized with control vector AdLacZ or PBS developed tumors in 14 days, demonstrating that tumor protection was Trp-2 specific (Fig. 1A) . To quantify the potency of the AdmTrp-2 and AdhTrp-2 vaccines, immunized mice were challenged by s.c. injection with 2 ϫ 10 4 to 1 ϫ 10 6 B16F10 cells. As summarized in Fig. 1B , immunization with AdmTrp-2 only protected mice against the lowest dose of B16F10 cells (2 ϫ 10 4 ), whereas 50-fold greater protective immunity was achieved by AdhTrp-2. Interestingly, all of the AdhTrp-2-immunized animals developed localized vitiligo at the vaccination sites, whereas those immunized with AdmTrp-2 did not ( Fig. 2 ; data not shown). These results suggest that autoimmunity is a function of the strength of the vaccine. Previous studies have demonstrated that CD4-dependent antitumor immunity may involve antibodies specific for tumor antigen as the final effector components in mediating tumor cell eradication (7, 10, 13) . Antibodies do not appear to be involved in either tumor protection or the development of vitiligo because B cell-deficient mice immunized i.d. with AdhTrp-2 were protected fully against B16F10 cells (Fig. 4 ) and developed vitiligo (Fig. 2 ).
Intramuscular Immunization with AdhTrp-2 Induces Strong Antigen-Specific Immune Responses without the Induction of Vitiligo.
A previous report demonstrated that the efficacy of an Ad-expressing human gp100 against B16 melanoma was route dependent (25) . In that study, i.d. immunization with Adhgp100 produced protective antitumor immunity, whereas i.m. injection did not. To determine whether the antitumor immunity and vitiligo observed in our experiments were route dependent, mice were immunized with AdhTrp-2 i.m. In contrast to the experiments with hgp100, mice immunized with AdhTrp-2 i.m. were protected from tumor challenge to the same extent as mice immunized i.d. (Table 1) . Strikingly, however, none of the mice in the i.m. group developed vitiligo.
The lack of vitiligo in the i.m. group may reflect differences in the antitumor effectors produced by the i.d. and i.m. groups. However, antitumor immunity induced by AdhTrp-2 i.m. depended on CD4 ϩ and CD8
ϩ T cells similarly to the i.d. group and was unaffected in B cell-deficient mice (data not shown). Thus, the discrepancy in vitiligo induction does not appear to reflect different effector mechanisms.
To compare further the immune responses elicited by AdhTrp-2 delivered i.m. and i.d., we measured the CD8 ϩ T-cell response to the vaccine using two functional assays: (a) in vivo cytotoxic activity and (b) direct ex vivo secretion of IFN-␥. To analyze Trp-2-specific cytotoxicity in vivo, syngenic spleen cells were pulsed with Trp-2 peptide (Trp-2 180 -188 ) and labeled with a high level of CFSE. OVA 257-264 peptide-pulsed syngenic spleen cells were labeled with a lower level of CFSE and used as control for antigen specificity. A 1:1 mixture of 5 ϫ 10 6 cells of each target cell population was injected i.v. into naive or AdhTrp-2-immunized mice. After 6 h, the presence of target cell populations in spleens was analyzed by flow cytometry. As shown in Fig. 5A , target cells pulsed with Trp-2 peptide were cleared selectively from mice immunized i.m. and i.d. To enumerate directly peptide-specific CD8
ϩ CTL in vaccinated mice, freshly isolated splenocytes were restimulated briefly (6 h) with Trp-2 180 -188 , and the frequency of IFN-␥-secreting CD8 ϩ T cells was measured by flow cytometry. An example of the results from the flow cytometry is provided in Fig. 5A ; i.m. and i.d. immunization with AdhTrp-2 could elicit Trp-2 180 -188 -specific CD8 ϩ T cells, whereas only background IFN-␥ production was observed in cultures containing OVA 257-264 . In repeated experiments, the response elicited i.m. actually was more potent than the response produced by i.d. immunization (Fig. 5B) . Although antibodies do not appear to be required for either antitumor immunity or vitiligo in this model, antibody production against Trp-2 provides a measure of vaccine potency. Serum samples were taken ϩ and CD8 ϩ T cells can mediate tumor rejection. C57BL/6 mice were immunized intradermally with adenovirus encoding human tyrosinase-related protein 2 (AdhTrp-2), challenged with 1 ϫ 10 5 B16F10 cells 14 days after immunization, and monitored for the onset of tumor formation. Antibody depletion was initiated 2 days before tumor challenge and then once a week until most control animals (PBS-injected mice) developed palpable tumors. The results are representative of two experiments with five mice for each group. ϩ CTL, i.m. immunization elicited a higher level of Trp-2-specific antibody production than i.d. injection (Fig. 5C) .
Vitiligo Can Be Induced by Inflammatory Stimuli in Mice Immunized Intramuscularly with AdhTrp-2. Because mice immunized by i.m. injection of AdhTrp-2 exhibit antitumor immunity comparable with those immunized by i.d. injection, the absence of vitiligo in the i.m. group simply cannot be a result of inadequate immunization. Interestingly, whereas vaccine-induced autoimmune vitiligo was observed consistently in all of the animals immunized with AdhTrp-2 i.d., the vitiligo was observed only around the injection site (Fig. 2) . This observation prompts us to hypothesize that vitiligo may be a consequence of inflammation in the skin following vaccination, leading to the recruitment of autoreactive T cells into the skin and subsequent vitiligo. Accordingly, we reasoned that if recruitment of autoreactive T cells into the skin was a necessary step for the induction of autoimmune vitiligo following AdhTrp-2 vaccination, we should be able to induce vitiligo in i.m. immunized mice by i.d. injection with nonspecific inflammatory stimuli. To first confirm the possibility that inflammation induced by the Ad vector was sufficient to recruit anti-Trp-2 effectors into the skin, we immunized mice with AdhTrp-2 i.m. and injected AdLacZ into the skin. As a control, mice were immunized with AdLacZ i.m. and subsequently with AdLacZ i.d. Consistent with our hypothesis, all of the mice immunized with AdhTrp-2 i.m. developed vitiligo at the skin site where the AdLacZ was injected, whereas the mice that were immunized with AdLacZ i.m. did not ( Table 2 ). To demonstrate further that the recruitment of the autoimmune effectors to the skin can result from nonspecific inflammation, mice were immunized with either AdhTrp-2 or AdLacZ i.m. followed by i.d. administration of Complete Freund's Adjuvant (CFA) or PBS. Again, the mice immunized with AdhTrp-2 developed vitiligo in the area where the CFA was injected, whereas those immunized with AdLacZ did not (Table 2) . Furthermore, vitiligo was not seen in AdhTrp-2-immunized mice that received i.d. challenge of PBS (Table 2) . Thus, these results clearly demonstrate that vitiligo in this model is the result of secondary inflammation within the target tissue and not a direct result of effective antitumor immunity.
DISCUSSION
A major concern for cancer vaccines is that an efficient immune response against self-tumor antigens may increase the risk of autoimmune sequelae (12) . A number of researchers have suggested that the induction of autoimmune disease is an inevitable consequence of generating effective antitumor immunity (7, 19, 20) . Evidence for this link comes from clinical trials in which vitiligo was correlated with clinical responses to interleukin 2 therapy in patients with metastatic melanoma (29) . This connection was supported additionally by animal studies in which protective antimelanoma immunity was associated largely with vitiligo development (7, 30) . However, research from our group and others has demonstrated that tumor rejection can be achieved without autoimmune consequences (11, 22, (31) (32) (33) . These conflicting results clearly indicate that additional studies are required to understand the mechanisms that lead to or prevent the occurrence of autoimmune consequence following cancer vaccination.
One simple explanation for the dissociation of antitumor immunity and autoimmune destruction in cancer vaccination studies is the differential level of a target antigen expressed by the tumor (high expression) and normal tissue (low expression; Refs. 34 -36) . Therefore, the lack of autoimmunity in some cancer vaccine models could reflect a weak vaccine that is able to eliminate a small number of tumor cells under experimental conditions without causing pathology in normal tissues. Supporting this hypothesis, vaccination with AdmTrp-2 i.d. in our model elicited modest protective immunity against a low dose of B16F10 cells (2 ϫ 10 4 ) without causing subsequent autoimmune vitiligo. Similar observations have been obtained in our studies of gp100-based vaccines and other investigations using different antigens and vaccination platforms (11, 22, (31) (32) (33) . Thus, it clearly is possible to elicit protective immunity against low-dose tumor cell challenge without subsequent autoimmune syndromes. However, protective immunity provided by immunization with AdmTrp-2 was lost when the challenge was increased to 1 ϫ 10 5 cells. To increase the potency of the Ad vaccine, we used hTrp-2 as the antigenic target because it has been shown previously that xenoantigens are more immunogenic than the native murine antigen (2, 3, 8 -11) . Vaccination with AdhTrp-2 provided protection against challenge with 1 ϫ 10 6 tumor cells, demonstrating the increased potency of the xenoantigen as a vaccine target. More importantly, all of the These results appear to contradict previous reports demonstrating that antitumor immunity elicited by a Trp-1-based vaccine always was associated with vitiligo (7, 10) . A possible explanation for this discrepancy is that immunity induced against two closely related autoantigens involves different mechanisms (i.e., vaccine-induced immunity against Trp-1 is mediated primarily by antibodies), whereas Trp-2-specific tumor protection depends on T cell-mediated responses (5, 10, 33) . Although our studies demonstrated that antibodies against Trp-2 were induced in wild-type mice immunized with AdhTrp-2, tumor protection and autoimmune vitiligo could be achieved in B cell-deficient mice, suggesting that antibodies have a minimal role. It is likely that Trp-1-specific antibodies can readily penetrate into the skin, resulting in the damage of normal melanocytes, whereas access to the skin by Trp-2-specific autoreactive T cells is extremely limited in the absence of inflammation. The observation that i.d., but not i.m., delivery of AdhTrp-2 induces vitiligo strongly supports the notion that a local inflammatory response is required to recruit Trp-2-specific effector T cells into the skin. To evaluate directly this hypothesis, we induced inflammation in the skin of mice immunized with AdhTrp-2 i.m. Two inflammatory agents were used: (a) AdLacZ and (b) CFA. All of the AdhTrp-2-immunized mice developed vitiligo around the site where the inflammatory agent was injected in the skin, whereas control mice that were challenged with PBS or immunized with AdLacZ did not develop any vitiligo. Furthermore, vitiligo also occurred in AdhTrp-2-immunized (i.m.) mice when their skin was bombarded twice with DNA (no specific antigen)-coated gold particles by gene gun or when they had skin lesions resulting from fights with cage-mates (data not shown). Thus, our results with the AdhTrp-2 model strongly support the concept that vitiligo following cancer vaccination is not a necessary outcome and may be a result of damage to the skin induced by local traumatic or inflammatory stimuli.
Colella et al. reported that whereas i.v. immunization with vaccinia virus expressing human tyrosinase could elicit a CTL response that cross-reacted with murine tyrosinase peptide, such autoreactive CTLs did not cause vitiligo in immunized mice (37). However, s.c. injection with a tyrosinase-specific CTL line derived from vaccinia/human tyrosinase-immunized mice induces vitiligo in the vicinity of the injection site, supporting our hypothesis that the skin access by effector T cells is required for the subsequent destruction of normal melanocytes (37) . Likewise, other studies demonstrated that immunotherapy-induced vitiligo occurred only in the area surrounding the site of tumor inoculation or skin depilation (5, 38, 39) . Consistent with our observation, vitiligo in these studies rarely is disseminated into other skin area.
Increasing evidence has pointed to a critical role of autoreactive T cells, including CD4 ϩ and CD8 ϩ T cells, in antitumor immunity; our results suggest that activation of either CD4 ϩ or CD8 ϩ T celldependent cellular effector pathway will not necessarily induce autoimmune consequences unless an inflammatory agent is introduced into the normal tissue. Our studies offer a new explanation for the inconsistent linkage between antitumor immunity and autoimmune pathology in preclinical models and suggest that it should be possible to design a cancer vaccine strategy that will not produce autoimmune sequelae.
